Dose study of bupivacaine for subarachnoid block cesarean section in sub-plateau area

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076935

Enrollment

Unknown

Registered

2023-10-24

Start date

2023-10-31

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subplateau drug consumption

Interventions

Upper and lower sequential group:The initial dose was 0.75% bupivacaine 12mg (1.6ml), 10% glucose solution 0.5ml, diluted to 3ml with preservative-free saline, and the adjacent dose was 0.75mg. The ef

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age: 20-40 years old, body mass index 18-28kg/m2, has been living in the local sub-plateau (2000m above sea level)

Exclusion criteria

Exclusion criteria: ASA > II, gestational age < 37 weeks, severe pregnancy complications, fetal or placental abnormalities such as premature rupture of membranes, intrauterine growth restriction, and contraindications for spinal anesthesia.

Design outcomes

Primary

Measure	Time frame
Sensory block plane;	—

Secondary

Measure	Time frame
Blood presure;HR;	—

Countries

china

Contacts

Public Contactyangchen

Obstetrics & Gynecology Hospital, Fudan University,

annie.114@163.com+86 136 7166 7155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026